Abstract:Actively targeted nanomedicines though conceptually attractive for tumor therapy are extremely hard to realize due to problems of premature drug leakage, excessive liver accretion, inadequate tumor uptake, and/or retarded drug release inside tumor cells. Here, we systemically studied the influence of disulfide crosslinking on the in vitro and in vivo performance of integrin-targeting micellar docetaxel (t-MDTX). Of note, t-M5DTX with a high disulfide content was clearly advantageous in terms of stability, intracellular drug release, anti-tumor activity toward αVβ3-overexpressing A549 cells, blood circulation and therapeutic efficacy in orthotopic A549-luc lung tumor-bearing mice. t-MDTX induced extraordinary tumor targetability with tumor-to-normal tissue ratios of 1.7-8.3. Further studies indicated that t-M5DTX could effectively eradicate αVβ3-overexpressing lung and prostate cancer patient-derived xenografts (PDX), in which ca. 80% mice became tumor-free. This integrin-targeting disulfide-crosslinked micellar docetaxel emerges as a promising actively targeted nanoformulation for tumor therapy. STATEMENT OF SIGNIFICANCE: Nanomedicines have a great potential in treating advanced tumor patients; however, their tumor-targeting ability and therapeutic efficacy remain unsatisfactory. In addition to PEGylation and ligand selection, particle size, stability and drug release behavior are also critical to their performance in vivo. In this paper, we find that small and cRGD-guided disulfide-crosslinked micellar docetaxel (t-MDTX) induces superior tumor uptake and retention but without increasing liver burden, leading to extraordinary selectivity and inhibition of αvβ3 overexpressing lung tumors. t-MDTX is further shown to effectively treat αvβ3-positive patient-derived tumor models, lending it a high potential for clinical translation.

Docetaxel Prodrug Liposomes for Tumor Therapy: Characterization, in Vitro and in Vivo Evaluation

Construction and Cellular Uptake Behavior of Redox-Sensitive Docetaxel Prodrug-Loaded Liposomes

Docetaxel-Loaded-Lipid-Based-Nanosuspensions (Dtx-Lns): Preparation, Pharmacokinetics, Tissue Distribution and Antitumor Activity

Reduction-Responsive Docetaxel Prodrug Encapsulated Within Human Serum Albumin Nanoparticles for Cancer Therapy.

Docetaxel-loaded Liposomes: Preparation, Ph Sensitivity, Pharmacokinetics, and Tissue Distribution

Preparation and studies of docetaxel proliposome

RGD(Arg-Gly-Asp) Internalized Docetaxel-Loaded Ph Sensitive Liposomes: Preparation, Characterization and Antitumor Efficacy in Vivo and in Vitro.

Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles.

Development of Polysorbate 80/phospholipid Mixed Micellar Formation for Docetaxel and Assessment of Its in Vivo Distribution in Animal Models

Docetaxel liposomes for lung targeted delivery: development and evaluation

Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.

Antitumor Effects of Docetaxel in Truncated Basic Fibroblast Growth Factor- Functionalized Liposomes Delivered by d-α-tocopheryl Polyethylene Glycol 2000 Succinate

A Novel Docetaxel Derivative Exhibiting Potent Anti-Tumor Activity and High Safety in Preclinical Animal Models.

A novel monomethoxy polyethylene glycol-polylactic acid polymeric micelles with higher loading capacity for docetaxel and well-reconstitution characteristics and its anti-metastasis study

Design of Carboxymethylcellulose-Conjugated Polymeric Prodrug Micelles for Enhanced in Vivo Performance of Docetaxel

Preparation and Evaluation of RGD and TAT Co-Modified Docetaxel-Loaded Liposome

Redox-sensitive prodrug nanoassemblies based on linoleic acid-modified docetaxel to resist breast cancers

Self-Delivering Prodrug-Nanoassemblies Fabricated by Disulfide Bond Bridged Oleate Prodrug of Docetaxel for Breast Cancer Therapy

Preparation, Characterization and Anti-Glioma Effects of Docetaxel-Incorporated Albumin-Lipid Nanoparticles

Efficacy, Pharmacokinetics, and Biodistribution of Thermosensitive Chitosan/β-Glycerophosphate Hydrogel Loaded with Docetaxel

Integrin-targeting Disulfide-Crosslinked Micellar Docetaxel Eradicates Lung and Prostate Cancer Patient-Derived Xenografts.